An observational study in Psoriasis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 12th largest by planned enrollment of the 14 observational ones that give a count, is one of 7 that started in 2025, is one of 14 observational ones, reaches primary completion later than 3 of the 13 other live ones, and was the 41st registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
Bristol-Myers Squibb · Sites in United States
Women only · Healthy volunteers
Bristol-Myers Squibb · Sites in France, Switzerland
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 1995; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 408 observational studies indexed under Psoriasis.
Median enrollment 131 across the 28 interventional studies, 528 across the 14 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
3 of the studies in Psoriasis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710470Bristol-Myers SquibbA Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring | 2027-01-31 |
| NCT06512337Bristol-Myers SquibbA Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China | 2027-03-11 |
| NCT07256015Bristol-Myers SquibbDeucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | 2027-07-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
The study population will consist of adults diagnosed moderate/severe psoriasis who have already started treatment with deucravacitinib according to clinical practice and to reimbursement criteria determined by the National Drug Agency (AIFA) in Italy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate/severe psoriasis receiving deucravacitinib
Drug: Deucravacitinib
According to the product label
The percentage of participants still receiving deucravacitinib treatment
Time frame: Week 24 and 52
Absolute Psoriasis Area and Severity Index (PASI)
Time frame: Baseline and Weeks 16, 24 and 52
Participant age in years
Time frame: Baseline
Participant sex
Time frame: Baseline
Participant height in cm
Time frame: Baseline
Participant body mass index in kg/m2
Time frame: Baseline
Participant previous pathologies
Time frame: Baseline
Participan previous surgical procedures
Time frame: Baseline
Date of psoriasis diagnosis
Time frame: Baseline
Number of participants with physical examination according to body systems
Time frame: Baseline
Participant treatment history
Treatment history to describe participants previous treatment(s) received for psoriasis and participants previous treatment(s) received not related to psoriasis
Time frame: Baseline
Participant comorbidities
Time frame: Baseline
Quality of life as assessed by the Dermatology Life Quality Index (DLQI) questionnaire
Time frame: Baseline and Weeks 16, 24 and 52
Change in symptoms as assessed by the Itch Numerical Rating Scale (Itch-NRS) score
Time frame: Baseline and Weeks 16, 24 and 52
Body Surface Area (BSA)
Time frame: Baseline and Weeks 16, 24 and 52
Static Physician's Global Assessment (sPGA) score
Time frame: Baseline and Weeks 16, 24 and 52
Scalp Specific Physician Global Assessment (ssPGA) score
Time frame: Baseline and Weeks 16, 24 and 52
Scalp Specific Physician Global Assessment (ssPGA) score 0/1
Time frame: Baseline and Weeks 16, 24 and 52
Absolute Psoriasis Area and Severity Index (PASI) 75 and 90
Time frame: Baseline and Weeks 16, 24 and 52
Concomitant psoriasis therapies received
Time frame: Baseline and Weeks 16, 24 and 52
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.
Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 23 months is below that.
Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.